Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study

Michel Weber,1 Laurent Velasque,2 Florence Coscas,3,4 Céline Faure,5 Isabelle Aubry,6 Salomon Y Cohen,7 on behalf of the RAINBOW study investigators

ABSTRACT

Background/aims To monitor treatment-naïve patients with wet age-related macular degeneration (wet AMD) receiving intravitreal aflibercept (IVT-AFL) in France.

Methods RAINBOW (Real life use of Intravitreal Aflibercept In FraNce - oBservational study in Wet age-related macular degeneration) is an ongoing, observational, retrospective and prospective 4-year study to assess visual (primary), anatomical and safety outcomes following IVT-AFL treatment in wet AMD patients. We report the interim 12-month outcomes in patients who have already been enrolled.

Results Safety data were analysed from 586 patients (safety analysis set); and effectiveness data were analysed from 502 patients with at least one follow-up (full-analysis set) and from 353 patients with visual acuity data at baseline and month 12. The mean (SD) best-corrected visual acuity (BCVA) was 56.7 (18.2) letters and the mean (SD) central retinal thickness (CRT) was 395.6 (140.5) µm at baseline. Most patients (76.9%) received a loading dose (first three injections within 90 days). The mean (SD) number of IVT-AFL injections over 12 months was 6.0 (2.1) and 6.6 (1.8) (patients who received a loading dose). The mean (SD) change in BCVA was 5.5 (15.0) letters and (2.1) and 6.6 (1.8) (patients who received a loading dose). The mean (SD) change in BCVA was 5.5 (15.0) letters and (2.1) and 6.6 (1.8) (patients who received a loading dose).

Conclusion This 12-month interim analysis showed that IVT-AFL was associated with sustained improvements in a real-world setting. The RAINBOW results are consistent with the VIEW clinical studies.

INTRODUCTION

It is estimated that 69 million adults in Europe will have age-related macular degeneration (AMD) by 2040.1 Most vision loss associated with AMD is caused by the neovascular/wet form of the disease.2 Anti-vascular endothelial growth factor (VEGF) agents have become increasingly popular in the treatment of this form of AMD. Intravitreal aflibercept (IVT-AFL) was approved for use in wet AMD in Europe in 2012, with bimonthly dosing (after three initial doses) and extension after 12 months. IVT-AFL is known to target VEGF and placental growth factor, which are key mediators in the progression of neovascularisation underlying wet AMD.34 IVT-AFL 2mg every 8 weeks (2q8) after three initial doses was shown to be noninferior to ranibizumab 0.5mg monthly, with comparable ocular safety, in the VIEW studies.35 However, the results achieved under strict protocols in randomised studies may not always

Key messages

What is already known about this subject?

► Most published observational studies in wet age-related macular degeneration (AMD) have largely been in patients treated with ranibizumab, mainly due to its earlier European approval in 2007. However, there is underdosing in clinical practice; this has been reported in several large-scale studies.

What are the new findings?

► This observational study of patients with wet AMD treated with intravitreal aflibercept in France showed that visual and anatomical outcomes were improved over a 12-month period. The outcomes were consistent with the VIEW randomised studies.

How might these results change the focus of research or clinical practice?

► These findings indicate that outcomes achieved in randomised studies can be achieved under real-world settings.
be achieved in routine practice; this has prompted an interest in real-world studies.

Most published observational studies have largely been in patients treated with ranibizumab, mainly due to its earlier European approval in 2007. Ranibizumab 0.5 mg was initially approved with monthly or as-needed dosing after a loading dose (induction) coupled with regular monitoring. However, these regimens may have contributed to undertreating in clinical practice; this has been reported in several large-scale studies.

The aim of this is to report the 12-month outcomes from the RAINBOW (Real life use of intravitreal Afibercept In FraNce - oBservatiOnal study in Wet age-related macular degeneration) study. RAINBOW is an observational study to monitor the effectiveness and safety of IVT-AFL when used in treatment-naive patients with wet AMD in routine clinical practices across France.

**MATERIALS AND METHODS**

RAINBOW is an ongoing, observational, 4-year study to monitor the effectiveness and safety of IVT-AFL in treatment-naive patients with wet AMD. Patients were included retrospectively and prospectively. The study was conducted in 55 centres across France. Patients who received their first IVT-AFL injection between January 2014 and March 2015 were screened and will be followed for a period of 4 years or until study discontinuation. Herein, we report the 12-month outcomes. No independent ethics committee and institutional review board approval was obtained due to its observational design in accordance with the requirements of local law and regulations in France; however, the protocol was reviewed and approved by a French data privacy committee (Comité Consultatif sur le Traitement de l’Information en Matière de Recherche dans le Domaine de la Santé and Commission Nationale de l’Informatique et des Libertés). All patients provided written informed consent to participate.

**Participants**

Patients aged ≥50 years diagnosed with wet AMD and prescribed IVT-AFL by their physician were eligible. Prior or current treatment with any anti-VEGF agent or macular laser in the study eye was not allowed. The study eye was defined as the worst-seeing eye of each patient, but the second eye was also considered if it was treatment naïve. Patients were excluded if they did not meet the indication criteria for IVT-AFL, if they had another retinal disease (diabetic retinopathy, diabetic macular oedema, myopic choroidal neovascularisation, retinal vein occlusion, central serous chorioretinopathy or angioid streaks) or if they were participating in any other interventional study.

**Assessments**

The primary aim was to evaluate the mean change in best-corrected visual acuity (BCVA) from baseline to 12 months. Other assessments included mean change in central retinal thickness (CRT) and safety outcomes at month 12. Patient medical records were evaluated for demographic and clinical characteristics. For retrospectively enrolled patients, resource use, tests, treatment(s) and outcomes were also obtained from medical records. For prospectively enrolled patients, this information was obtained.

### Table 1 Demographic and baseline characteristics

| Characteristic                                      | Patients (n=586) |
|-----------------------------------------------------|-----------------|
| Age, years                                          | 79.7 (7.8)      |
| Female, n (%)                                       | 358 (61.1)      |
| Study eye, n (%)                                    |                 |
| Right                                               | 310 (52.9)      |
| Left                                                | 276 (47.1)      |
| Both                                                | 76 (13.0)       |
| Duration of wet AMD, months (n=572)*                | 1.1 (6.8)       |
| BCVA (letters) score (n=502; FAS)                   | 56.7 (18.2)     |
| BCVA (letters) score (n=353; FAS targeted)          | 57.7 (17.8)     |
| BCVA (letters) score (n=284; FAS targeted with loading dose) | 57.2 (17.8)     |
| BCVA (letters) categories, n (%) (n=502)            |                 |
| <50                                                 | 138 (27.5)      |
| 50–55                                               | 63 (12.5)       |
| 55–70                                               | 148 (29.5)      |
| ≥70                                                 | 153 (30.5)      |
| Central retinal thickness, µm (n=446; FAS)*         | 395.6 (140.5)   |
| Central retinal thickness, µm (n=346; FAS with loading dose)* | 402.6 (143.1)   |
| Subretinal fluid, n (%) (n=474)*                    | 385 (81.2)      |
| Intraretinal fluid, n (%) (n=474)*                  | 296 (62.4)      |
| Pigment epithelium detachment, n (%) (n=474)*       | 305 (64.3)      |
| Choroidal neovascularisation, n (%) (n=373)*        |                 |
| Occult                                              | 124 (33.2)      |
| Predominantly classic                               | 74 (19.8)       |
| Retinal choroidal anastomosis                       | 43 (11.5)       |
| Minimally classic                                   | 35 (9.4)        |
| Retinal pigment epithelium detachment               | 30 (8.0)        |
| Polypoidal choroidal vasculopathy                   | 11 (2.9)        |
| Other                                               | 56 (15.0)       |
| Intraocular pressure, mm Hg (n=280)*                | 14.8 (3.1)      |
| Diabetes, n (%)                                     | 56 (9.6)        |
| Hypertension, n (%)                                 | 212 (36.2)      |
| Cardiovascular diseases, n (%)                      | 96 (16.4)       |

Mean (SD) unless stated.

*Data not available for all patients.

AMD, age-related macular degeneration; BCVA, best-corrected visual acuity.
recorded at routine follow-up visits. All adverse events (AEs) occurring after the first injection of IVT-AFL were documented in the electronic case report form.

**Statistical analyses**

It was estimated that 600 patients should be screened in order to achieve approximately 390 usable patient datasets at 4 years. These estimates were based on the VIEW studies, using a 10% annual dropout rate. Safety analyses were based on data from patients who received at least one IVT-AFL injection (safety analysis set). Effectiveness analyses (resource use and anatomical outcomes) were based on patients who also had documented assessments in the study eye at baseline and at least one follow-up visit (full analysis set, FAS), and visual acuity analyses were based on patients who had documented visual acuity assessments at baseline and month 12 (FAS targeted). Outcomes were also assessed in patients who received a loading dose (the first three IVT-AFL injections within 90 days).

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) letter chart or any visual scale. The visual acuity readings were then converted to a standardised score using a conversion chart (online supplementary table 1). Final visual outcomes were also categorised by the percentage of patients who gained 0–4, 5–9, 10–14 or ≥15 letters, the percentage of patients who lost >15 letters, and by visual acuity categories (<50, [50–55], [55–70] and ≥70 letters) at month 12. Outcomes were also assessed in subgroups based on presence of fluid or pigment epithelium detachment (PED) at baseline and injection (<7, ≥7) categories; the injection categories were used to compare with other real-world studies, such as LUMINOUS. Lesion type was defined according to fluorescein angiography and indocyanine green examinations.

The statistical analyses were exploratory and descriptive. The mean changes in BCVA and CRT from baseline to month 12 were analysed using t-tests, with a significance level of 5%. Sensitivity analyses were also performed on visual acuity outcomes using a last observation carried forward (LOCF) approach to account for missing data and replacement by the median population values; these were performed using the FAS population. All statistical analyses were performed using SAS Enterprise Guide V.7.13 (SAS Institute).

**RESULTS**

**Participants**

A total of 615 patients were screened. Safety data were analysed from 586 patients (safety analysis set). Resource use, anatomical outcomes and sensitivity analyses were determined using data from 502 patients (FAS) and visual acuity outcomes were analysed from 353 patients with visual acuity data at baseline and month 12 (FAS targeted) (see online supplementary figure 1). The baseline characteristics are shown in table 1. Most patients underwent fluorescein angiography examination (75.4%; n=377/500) and indocyanine green examination (56.4%; n=282/500) at baseline. Most patients (76.9%: n=386/502) also received an IVT-AFL loading dose. The mean (SD) number of IVT-AFL injections over 12 months was 6.0 (2.1) (n=502) and 6.6 (1.8) in patients who received a loading dose (n=386). Most patients were treated with ‘as-needed’, ‘treat and extend (T&E)’
or ‘observe and plan’ protocols; 9.8% (n=49/502) of patients received three initial IVT-AFL injections followed by treatment every 8 weeks.

Only 13.5% of patients (n=68/502) switched treatment during the study, with most switching to another anti-VEGF agent (82.4%; n=56/68), predominantly ranibizumab (96.4%; n=54/56). The main reasons for switch included lack of effectiveness (73.5%; n=50/68), AEs/serious AEs (SAEs) (2.9%; n=2/68) and other/unknown reason (23.5%; n=16/68). Some patients switched back from ranibizumab to IVT-AFL (38.9%; n=21/54) (reasons not recorded). The mean (SD) number of clinic visits was 9.4 (2.3) and 9.8 (2.0) (patients who received a loading dose).

Visual and anatomical outcomes

The mean (SD) change in BCVA was 5.5 (15.0) letters (n=353) and 6.8 (14.5) letters in patients who received a loading dose (n=284) (both p<0.001) at month 12 (figure 1). The mean (SD) change in BCVA using an LOCF approach was 4.5 (15.9) letters (n=502) and 5.8 (15.2) letters in patients who received a loading dose (n=386) (both p<0.001 vs baseline) at month 12. The mean (SD) change in BCVA using replacement by the population median was 7.8 (16.7) letters (n=502) and 8.1 (15.7) letters in patients who received a loading dose (n=386) (both p<0.001 vs baseline) at month 12.

The proportions of patients who gained ≥15 letters were 25.2% (n=89/353) and 28.9% in patients who received a loading dose (n=82/284) (figure 2A). When patients were stratified according to baseline visual acuity categories (<50, [50–55], [55–70] and ≥70 letters), the mean (SD) numbers of injections in these categories were 6.3 (1.9), 6.9 (2.0), 6.2 (1.9) and 6.1 (2.0), and the mean (SD) letter changes were 12.3 (16.7), 11.1 (15.3), 10.4 (14.9) and 10.8 (15.2) letters at month 12, respectively.

Figure 2. Visual acuity outcomes in patients (FAS targeted) receiving IVT-AFL based on (A) 0–4, 5–9, 10–14 and ≥15 letter gains or >15 letter loss at month 12 and (B) the mean letter gains when patients were stratified by final visual acuity groups at month 12 (treatment decisions were made by the physician). *P<0.001 versus baseline. BCVA, best-corrected visual acuity; FAS, full analysis set; IVT-AFL, intravitreal aflibercept.
The percentages of patients with BCVA ≥ 70 letters were 45.9% (n=162/353) and 45.4% (patients who received a loading dose; n=129/284) at month 12 (online supplementary figure 2).

There was also a significant mean (SD) reduction in CRT at month 12; the mean (SD) change was –108.7 (146.8) (n=333) and –116.4 (150.4) µm in patients who received a loading dose (n=275) (both p<0.001 vs baseline) (figure 3). These improvements were evidenced by month 3, and maintained through month 12.

Subgroups

The mean change in BCVA (letters) was significantly improved in patients (n=353) with intraretinal or subretinal fluid or PED at baseline (all p<0.001). There were mean BCVA improvements of 6.8 letters in patients who received ≥7 injections (n=165) and 4.3 letters in patients who received <7 injections (n=188) (online supplementary table 2). There was also a reduction in the proportion of patients (n=474) with fluid (intraretinal, subretinal and subretinal pigment epithelium) and PED over the 12-month study (online supplementary table 3). Choroidal neovascularisation leakage reduction was also observed.

Safety

Overall, 20.1% (n=118/586) of patients experienced at least one treatment-emergent AE (TEAE), and 1.9% experienced at least one treatment-related TEAE (table 2). The most common ocular AEs were vitreous floaters (1.9%), lacrimation increased (1.0%) and eye pain (0.9%). The most common nonocular AEs included product use issue (2.9%), cardiac failure (0.9%), bronchitis (0.9%) and drug hypersensitivity (0.9%). Serious AEs were reported in 3.9% of patients. There was one treatment-related transient ischaemic attack.

DISCUSSION

This 12-month interim analysis of the RAINBOW study showed that visual and anatomical improvements were achieved in treatment-naïve patients with wet AMD receiving IVT-AFL in a real-world setting. The outcomes observed in patients who received a loading dose (first three injections within 90 days) were favourable compared with those achieved in randomised studies. In the VIEW studies, the mean change in BCVA was 8.4 letters, the percentage of patients gaining ≥15 letters was 30.9% and the percentage of patients maintaining visual acuity (losing <15 letters) was 95.3% at month 12 in the combined IVT-AFL 2mg bimonthly group (2q8) after three loading doses. These patients received ~7.5 IVT-AFL injections over 12 months. There were, however, some differences in baseline characteristics between RAINBOW and VIEW. The mean age and baseline BCVA were both higher in RAINBOW than VIEW, and the BCVA was outside the VIEW inclusion criteria in about 20% of patients enrolled in RAINBOW (<25 letters in 7.9% and >73 letters in 13.2%, respectively). The IVT-AFL regimen in the RAINBOW study was also different from VIEW, with only 10% of patients receiving the same protocol. Another observational study in the UK, which monitored treatment-naïve patients with wet AMD (58 eyes) receiving IVT-AFL bimonthly treatment (after a loading dose), reported similar visual outcomes to RAINBOW. The baseline BCVA was 54.1 ETDRS letters, and the mean improvement in BCVA was 4.67 letters at month 12; 17.2% of patients gained ≥15 letters, and 96.6% of patients avoided losing >15 letters at month
The mean reduction in CRT was lower (−35.36 µm) than in RAINBOW, but the baseline CRT was also lower (284.2 µm). The mean number of IVT-AFL injections was similar (7.1), but the mean number of clinical visits was lower (4). These authors used fixed IVT-AFL dosing. The IVT-AFL regimen used in RAINBOW was more variable and may warrant further investigation.

RAINBOW also highlighted an improvement in outcomes with IVT-AFL compared with earlier observational studies (such as AURA) that monitored ranibizumab. There may be a number of reasons for this, including improvements in patient management (a number of ranibizumab studies were published several years ago) and differences in dosing regimens between the two agents. For example, in the AURA study, which monitored outcomes in 2227 patients with wet AMD, visual acuity declined over time to 2.4 letters at year 1 and 0.6 letters at year 2, and the mean number of ranibizumab injections was 5.0 at year 1 and 2.2 at year 2. In the French cohort of AURA, which comprised 398 patients, the mean change in visual acuity was 0.8 letters at year 1 and −1.1 letters at year 2, the mean number of ranibizumab injections was 4.4 (year 1) and 1.9 (year 2), and the mean number of visits was 8.5 (year 1) and 4.9 (year 2). More recent ranibizumab studies have reported variable results. A larger analysis of 18 358 eyes from 20 real-world studies also found that outcomes did not reflect those reported in randomised studies. In this analysis, the mean change in visual acuity was 2.9 letters at year 1 and the mean number of ranibizumab injections was 5.5. In comparison, interim findings from the ongoing LUMINOUS study showed that the mean change in BCVA was 4.7 in 706 treatment-naïve patients with wet AMD.10 A recent meta-analysis of ~26 360 patients from 42 real-world studies reported better outcomes with ranibizumab T&E compared with as-needed, which was used in some earlier studies. The mean change in visual acuity was 8.8 versus 3.5 letters and the mean number of injections was 6.9 versus 4.7 at year 1, respectively. Unfortunately, outcomes by IVT-AFL regimen (as-needed, T&E or observe and plan) were not explored in this interim analysis of RAINBOW.

RAINBOW also showed that IVT-AFL was well tolerated in clinical practice. However, the incidence of ocular AEs was generally lower in RAINBOW than in VIEW, which may be due to differences in reporting of AEs between randomised and observational studies, with the possibility of under-reporting. These findings were, however, consistent with the known safety profile of IVT-AFL in wet AMD.5 6

It must be noted that there are a number of limitations inherent with the observational design of the RAINBOW study. Evaluation of visual acuity was performed using ETDRS letter charts or any other visual scale in this study. However, the use of different charts may introduce bias, especially in the measurement of the number of letters gained or lost after treatment. The findings are also based

| AE, n (%) | Patients (n=586) |
|-----------|------------------|
| Any AE    | 118 (20.1)       |
| Any TEAE  | 118 (20.1)       |
| Any treatment-related TEAE | 11 (1.9) |
| Any ocular TEAE (study eye) | 8 (1.2) |
| Most common ocular AE (>0.5%) |                |
| Vitreous floaters | 11 (1.9) |
| Lacrimation increased | 6 (1.0) |
| Eye pain | 5 (0.9) |
| Photophobia | 4 (0.7) |
| Dry eye | 4 (0.7) |
| Conjunctivitis | 4 (0.7) |
| Eye irritation | 3 (0.5) |
| Conjunctival haemorrhage | 3 (0.5) |
| Eye pruritus | 3 (0.5) |
| Vision blurred | 3 (0.5) |
| Visual impairment | 3 (0.5) |
| Endophthalmitis | 0 (0.0) |
| Any SAE (>0.3%) | 23 (3.9) |
| Cancer | 3 (0.5) |
| Confusional state/disorientation | 3 (0.5) |
| Ischaemic stroke | 3 (0.5) |
| Any nonocular TEAE |                |
| Most common nonocular AE (>0.5%) |                |
| Product use issue | 17 (2.9) |
| Cardiac failure | 5 (0.9) |
| Bronchitis | 5 (0.9) |
| Drug hypersensitivity | 5 (0.9) |
| Injection site pain | 4 (0.7) |
| Malaise | 4 (0.7) |
| Falls | 4 (0.7) |
| Gastroenteritis | 3 (0.5) |
| Pneumonia | 3 (0.5) |
| Vertigo | 3 (0.5) |
| Back pain | 3 (0.5) |
| Osteoarthritis | 3 (0.5) |
| Ischaemic stroke | 3 (0.5) |
| Syncope | 3 (0.5) |
| Death (not treatment related) |                |
| Sudden | 3 (0.5) |
| Secondary to AE | 6 (1.0) |
| Any TEAE leading to discontinuation | 6 (1.0) |
| Transient ischaemic attack | 1 (0.2) |
| Any treatment-related TEAE leading to discontinuation | 0 |
on one European country, which may not be representative of other European countries and their respective reimbursement strategies.

In conclusion, this 12-month analysis highlights the effectiveness and safety associated with IVT-AFL in treatment-naïve patients with wet AMD in routine practice. Patients who received a loading dose also experienced better outcomes at month 12, although the correlation needs to be established by a multivariate analysis as these patients also received a mean of 0.6 more IVT-AFL injections. Ocular TEAEs were also consistent with the known safety profile of IVT-AFL. RAINBOW showed that these patients also received a mean of 0.6 more IVT-AFL needs to be established by a multivariate analysis as these patients also received a mean of 0.6 more IVT-AFL injections. Ocular TEAEs were also consistent with the known safety profile of IVT-AFL. RAINBOW showed that these patients also received a mean of 0.6 more IVT-AFL

**Acknowledgements**

Medical and scientific coordination were performed by Armelle Bailou-Beaufils, Head of Ophthalmology Department (Bayer France) and Ingrid Dutour, Clinical Research and Medical Advisor (Bayer France). Operational coordination was performed by Anne Marie Delaunay, Head of PMS Group (Bayer France).

**Collaborators**

The RAINBOW study investigators: Professor Salomon Yves Cohen, Dr Patrick Simon, Dr Alain Donati, Dr Valérie Krivcic, Dr Martine Mauguet Fayssse, Dr Frédéric Queguiner, Dr Sophie Navarre, Dr Concetta Li Calzi, Dr Elodie Bousquet, Dr Frédéric Chiambaretta, Dr Sylvia Nsighem-Butfet, Professor Catherine Crezot Garcher, Dr Isabelle Aviron, Professor Michel Weber, Dr Sébastien Bruneau, Dr Bertille Tourne de Massiac, Dr Jean-François Boulet, Dr Aude Danan Husson, Dr Mathieu Lehmann, Dr Eve Rousseau, Dr Franck Fajkunich, Dr Joël Uzzan, Dr Saddek Mohand Said, Dr Olivier Lebreton, Dr Houiem Jeguirim, Professor Carl Arndt, Dr Bénédicte Frioud Joulain, Dr Corinne Gonzalez, Professor Frédéric Matonti, Dr Isabelle Sillaire Houtmann, Dr Gabriel Quentel, Dr Amélie Lecleire-Collet, Dr Jean-François Girmens, Dr Hélène Massé, Dr Claire Scemmama, Dr Jonathan Benesty, Dr Anne Robinet Combes, Professor Corinne Dot, Dr Jean-Claude Mattei, Dr Claire Scemmama, Dr Jonathan Benesty, Dr Anne Robinet Combes, Professor Corinne Dot, Dr Jean-

3. **Authors' affiliations**

1. CHU Hôtel-Dieu, Nantes, France
2. Centre du Palais Gallien, Bordeaux, France
3. Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
4. Hôpital privé Saint Martin, Ramay Générale de Santé, Caen, France
5. Centre Ophtalmologique des Arceaux, Montpellier, France
6. Centre d’oïologie de Lie, Paris, France

**Presented at**

Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) (1–5 May 2016, Seattle, Washington), 16th European Society of Retina Specialists Congress (16th EURINTEXA) (08–11 September 2016 / Copenhagen, Denmark), Imaging & Managing Macular Diseases (Maculart) meeting (2–4 July 2017; Paris, France), 123e Congres de la Societe Francaise d’Ophthalmologie (SFO 23rd Congress) (05–09 May 2017, France, Paris). 49th Annual Congress of the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) (28 October to 01 November 2017, Perth, Australia).

**Funding**

The RAINBOW study was funded by Bayer Pharmaceuticals. The funding organisation participated in the design and conduct of the study, analysis of the data and preparation of the manuscript.

**Competing interests**

MW: Alcon, Alimera, Allergan, Bayer, Novartis, Thea; FC: Allergan, Bayer, Novartis, Roche; CF: Alcon, Bayer, Novartis; IA: Bayer; Novartis; S-VC: Alcon, Allergan, Bayer, Novartis, Thea.

**Patient consent for publication**

Obtained.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data sharing statement**

Availability of the data underlying this publication will be determined according to Bayer’s commitment to the EFPIA/PhRMA “Principles for responsible clinical trial data sharing”. This pertains to scope, time point and process of data access. As such, Bayer commits to sharing upon request from qualified scientific and medical researchers patients-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal. Data access will be granted to anonymized patient-level data, protocols and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**

1. Wong WL, Xu X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–e116.

2. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640–2.

3. Ablonczy Z, Dahrouj M, Marneros AG. Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels. FASEB J. 2014;28:2369–79.

4. Chen LJ, Ma L, Chu WK, et al. Identification of PFG as a New Gene for Neovascular Age-Related Macular Degeneration in a Chinese Population. Invest Ophthalmol Vis Sci 2016;57:1714–20.

5. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537–48.
6. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193–201.

7. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015;99:220–6.

8. Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye 2016;30:270–86.

9. Kim LN, Mehta H, Barthelmes D, et al. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2016;36:1418–31.

10. Capuano V, Oubraham-Mebroukine H, Wolff B, et al. Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUSTM study. Annual meeting of the association-for-research-in-vision-and-ophthalmology (ARVO); May 2016, Seattle, USA: ASSOC RESEARCH VISION OPHTHALMOLOGY INC

11. Warwick AN, Leaver HH, Lotery AJ, et al. Fixed bimonthly aflibercept in naïve and switched neovascular age-related macular degeneration patients: one year outcomes. Int J Ophthalmol 2016;9:1156–62.